Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Timothy L. Frankel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5987-0404; OpenAlex author ID A5103162178; NIH RePORTER profile ID 12560001. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 5)
Trials
0
Grants
3
Labs led
1
Collaborators
95
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 4 papers, 1 grant · 2026: 6 papers, 2 grants

Papers 26

  1. Elevated T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Expression and Immune Cell Dysfunction Characterize Complex Proteins Associated With SET1 (COMP… Co-author DOI 10.1016/j.modpat.2026.100972↗
  2. Wilms Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-25-1014↗
  3. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  4. Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization. Last author DOI 10.1158/2159-8290.cd-25-0377↗
  5. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
  6. Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1300↗
  7. Pancreatic cancer precursor lesions - Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma? First author DOI 10.1016/j.canlet.2025.217662↗
  8. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  9. Mouse Models for Pancreatic Ductal Adenocarcinoma are Affected by the cre-driver Used to Promote KRAS G12D Activation. Co-author DOI 10.1016/j.jcmgh.2024.101428↗
  10. Aspartate Transaminases Are Dispensable for Pancreatic Development and Pancreatic Cancer Progression Co-author DOI 10.64898/2025.12.17.694916↗
  11. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  12. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. Last author DOI 10.3390/ijms25052953↗
  13. Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression. Co-author DOI 10.1016/j.isci.2023.107408↗
  14. DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-21-0725↗
  15. Immunotherapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.26312↗
  16. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Da… Co-author DOI 10.1097/sla.0000000000003242↗
  17. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  18. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  19. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗
  20. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗
  21. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  22. Metabolism and epigenetics of pancreatic cancer stem cells. Last author DOI 10.1016/j.semcancer.2018.09.008↗
  23. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Co-author DOI 10.1158/0008-5472.can-19-0761↗
  24. Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28. Last author DOI 10.1016/j.jss.2018.07.015↗
  25. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiolo… Co-author DOI 10.1245/s10434-017-5810-x↗
  26. Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Co-author DOI 10.1016/j.bbrep.2016.06.004↗

Grants 3

  1. Mechanisms of myeloid cell driven pancreatic plasticity and carcinogenesis R01CA268426↗
  2. Fibroblast orchestration of the immune response in pancreatic cancer U01CA274154↗
  3. Role of environmental toxins in shaping the tumor immune microenvironment I01BX005777↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 15 shared papers, 2 shared grants, 2018–2026 · strength 4.34
  2. Filip Bednar · 15 shared papers, 2019–2026 · strength 2.47
  3. Costas Andreas Lyssiotis · 10 shared papers, 1 shared grant, 2016–2026 · strength 2.15
  4. Eileen S. Carpenter · 11 shared papers, 2020–2026 · strength 1.79
  5. Jiaqi Shi · 9 shared papers, 2019–2026 · strength 1.62
  6. Howard C. Crawford · 5 shared papers, 1 shared grant, 2019–2026 · strength 1.37
  7. Padma Kadiyala · 6 shared papers, 2024–2026 · strength 1.16
  8. Ahmed M. Elhossiny · 6 shared papers, 2024–2026 · strength 1.16
  9. Vaibhav Sahai · 7 shared papers, 2020–2026 · strength 1.07
  10. Katelyn L. Donahue · 6 shared papers, 2020–2026 · strength 0.91
  11. Yaqing Zhang · 4 shared papers, 2026 · strength 0.86
  12. Thomas Enzler · 2 shared papers, 2024–2025 · strength 0.76
  13. Hari Nathan · 6 shared papers, 2017–2024 · strength 0.76
  14. Nina G. Steele · 6 shared papers, 2020–2025 · strength 0.66
  15. Brian D. Griffith · 3 shared papers, 2024–2026 · strength 0.66
  16. Samantha B. Kemp · 6 shared papers, 2019–2025 · strength 0.64
  17. Emily L. Lasse Opsahl · 3 shared papers, 2025–2026 · strength 0.62
  18. Zeribe C. Nwosu · 4 shared papers, 2021–2026 · strength 0.51
  19. Valerie Gunchick · 4 shared papers, 2020–2025 · strength 0.49
  20. Wei Yan · 2 shared papers, 2026 · strength 0.43
  21. Dominik Awad · 2 shared papers, 2025–2026 · strength 0.39
  22. Theodore Steven Lawrence · 3 shared papers, 2019–2022 · strength 0.36
  23. Benjamin Allen · 3 shared papers, 2020–2025 · strength 0.35
  24. Joyce K. Thompson · 2 shared papers, 2019–2025 · strength 0.34
  25. Jorge D. Machicado · 2 shared papers, 2024–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.